Neuropeptide Research Mixture — Low-molecular-weight peptides with neurotrophic activity for neuroprotection, neuroplasticity, and BDNF pathway research
Entry research supply — ideal for initial neuroprotection and synaptic plasticity pathway studies
Extended supply for longitudinal neuroplasticity and BDNF signaling research protocols
Multi-vial kit for comprehensive neuropeptide research programs with multiple protocols
Every Cerebrolysin batch is quality-verified for neuropeptide content. Full COA provided with every order.
Premium neuropeptide mixture from $49.99 — competitive research pricing for high-quality product.
Ships within 24–48 hours. Cold-chain packaging available. Tracked USA delivery on every order.
Full COA confirming neuropeptide content, purity profile, and batch traceability with every shipment.
| Product Name | Cerebrolysin Research Solution |
| Composition | Low-molecular-weight neuropeptide mixture |
| Peptide Content | ~25% neuropeptide fraction by protein |
| Molecular Weight Range | <10 kDa (active peptide fraction) |
| Purity | ≥99% (HPLC verified) |
| Form | Sterile solution |
| Storage | 2–8°C; protect from light |
| Available Sizes | 5mL, 10mL |
Cerebrolysin is a neuropeptide mixture studied for its neurotrophic and neuroprotective activities. Research applications include investigating neuroplasticity mechanisms, BDNF-like signaling pathways, synaptic plasticity, and neuroprotective mechanisms in neuronal cell culture and animal model studies.
Cerebrolysin contains a complex mixture of low-molecular-weight peptides including fragments with activity at BDNF, NGF, and CNTF receptors. Identified components include peptides from the FPE peptide family that have been studied independently for their neurotrophic activities.
Yes — every Cerebrolysin order includes a Certificate of Analysis confirming neuropeptide content, batch identity, purity profile, and sterility testing for complete research documentation.
Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids studied as part of the neurotrophic research compound category. It is investigated in pre-clinical and in-vitro research models for its activity on neurotrophic and neuroprotective signaling pathways studied in vitro. The compound is supplied as a lyophilized powder of ≥99% HPLC-verified purity and is intended exclusively for laboratory research use under qualified scientific supervision.
AscendLabz Cerebrolysin is sourced from cGMP-aligned synthesis facilities and validated for identity, purity, and counter-ion content prior to release. Each lot is independently tested by HPLC, and a Certificate of Analysis (COA) detailing peak area, retention time, and batch number is provided with every order. This level of documentation is intended to support reproducible research and clear chain-of-custody record-keeping in academic and independent laboratory environments.
For research workflows, Cerebrolysin is most commonly characterized in cell-culture and isolated-tissue models where investigators examine neurotrophic peptide-mixture signaling alongside complementary compounds in the nootropic / neuropeptide research compounds class. Reference standards and dose-response controls should be established by each laboratory prior to experimental use, and all material should be handled by trained personnel using appropriate personal protective equipment.
Storage: Cerebrolysin ampoules are stable at 2-8°C protected from light. Do not freeze. Use ampoules immediately after opening. Lyophilized peptides should be kept in original sealed packaging until use to prevent moisture uptake.
Reconstitution: Bring the lyophilized vial to room temperature before opening. Reconstitute with ready-to-use solution by injecting solvent down the inner wall of the vial; do not direct the stream onto the lyophilized cake. Gently swirl — do not vortex or shake — until fully dissolved. Allow 5-10 minutes for complete solvation.
Handling: Use sterile technique throughout. Wipe vial septa with isopropyl alcohol before each draw. Document reconstitution date, solvent volume, and resulting concentration on the vial label for traceability.
Every batch of Cerebrolysin is analyzed by reverse-phase HPLC and confirmed to be ≥99% pure. Mass spectrometry confirms molecular identity, and counter-ion / residual-solvent panels are performed where applicable. The full Certificate of Analysis ships with each order and is also archived by lot number.
No. Cerebrolysin is supplied strictly for in-vitro laboratory research and is not approved by the FDA, EMA, or any regulatory authority for human or veterinary therapeutic use. It must not be administered to humans or animals. By purchasing, you confirm you are a qualified researcher and the material will be used only in a controlled laboratory setting.
All orders ship from the USA via tracked courier within 24-48 hours of payment confirmation. Domestic delivery typically arrives within 2-5 business days in discreet, temperature-stable packaging. Tracking is provided by email at the time of dispatch.
AscendLabz prices Cerebrolysin competitively while maintaining ≥99% HPLC-verified purity and a full COA. Bulk-vial bundles offer additional savings for laboratories ordering multi-month research supply. Pricing is reviewed monthly to remain among the most affordable verified-purity sources in the United States.
Cryptocurrency (Bitcoin, Ethereum, USDC, and others) is accepted with automatic discounts at checkout. Credit and debit cards are also supported through our secure payment processor. All transactions are encrypted end-to-end and order details are never shared with third parties.
Yes. Most laboratories order Cerebrolysin together with complementary compounds from the nootropic / neuropeptide research compounds category. Combined orders ship together with a single COA package and qualify for bulk-tier pricing. See the related compounds section below for commonly paired research peptides.
⚠️ Research Use Only
All products are strictly for laboratory research purposes only. Not for human consumption. Cerebrolysin has not been approved by the FDA for therapeutic use in the United States. For in vitro research and scientific study only.